Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Grant of Patent'.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has been granted a patent (Patent No. 573119) by the Indian Patent Office for a 'Dual Release Gastro-Resistant Composition' on October 31, 2025. The patent covers a next-generation Dual Release Proton Pump Inhibitor (PPI) tablet designed for patients with moderate to severe or treatment-resistant GERD (gastroesophageal reflux disease). The formulation uses unique tablet-in-tablet technology to release the medicine in two phases — 50% in the duodenum and 50% in the ileum — providing extended relief with a once-daily dose. The product has already received DCGI approval, and the patent is valid for 20 years from November 19, 2022. GERD affects around 14% of the global population (about 784 million people) and 15.6% of India's population, representing a large addressable market.
This strengthens Akums' intellectual property portfolio in the high-volume acid reflux therapy segment, potentially giving it exclusive manufacturing and licensing advantages. Positive for the stock as it signals innovation capability and potential for premium pricing or partnership deals, though near-term revenue impact is not quantified.